

Curriculum Vitae

Personal information

First name / Surname	Teresa Beninato
Telephone	+39 02 2390 3648
E-mail	teresa.beninato@istitutotumori.mi.it

Position

01/02/2023 - Today	Medical Oncologist, Department of Medical Oncology Foundation IRCCS Istituto Nazionale dei Tumori, Milan, Italy Thoracic cancer unit
--------------------	--

Work experience

01/02/2023 - Today	Medical Oncologist, Department of Medical Oncology Foundation IRCCS Istituto Nazionale dei Tumori, Milan, Italy Thoracic cancer unit
29/12/17 – 29/12/2022	Specialist registrar, Department of Medical Oncology Foundation IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico and ASST Santi Paolo e Carlo, Presidio Ospedaliero San Paolo and University of Milan, Milan, Italy
05/05/2021 – 04/08/2021	Vaccination campaign for Covid-19 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Education and training

August 2024 – Today	PhD student, INT-OU PhD programme in Life and Biomolecular Sciences , project title: Exploring the interplay between cell plasticity and immunity in small cell lung cancer in relation to treatment response.
14-16/09/2023	“Nibit Foundation Master's Course in Immuno-Oncology” Nibit Foundation
12/10/2023	Basic Life Support-Defibrillation Certificate Italian Resuscitation Council (IRC)
11/01/2023	Specialization in Medical Oncology, with full marks 70/70 cum laude Università Statale di Milano, Milano, Italia Thesis: PEOPLE NCT03447678: A PHASE II TRIAL TO TEST PEMBROLIZUMAB AS FIRST-LINE TREATMENT IN ADVANCED NSCLC PATIENTS WITH LOW PD-L1. A MULTIOMICS APPROACH
28/11/2022	GCP Training
01/10/2018 – 29/12/2022	Specialist registrar, Department of Medical Oncology

	Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy Genitourinary Cancer Unit, Thoracic Cancer Unit, Sarcoma Cancer Unit, Melanoma Cancer Unit, Breast Cancer Unit, Head and Neck Cancer Unit, Palliative Care Unit, Supportive Care Unit																														
01/07/18 – 30/09/18	Specialist registrar, Department of Internal Medicine Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico and University of Milan, Milan, Italy																														
29/12/17 – 30/06/18	Specialist registrar, Department of Medical Oncology ASST Santi Paolo e Carlo, Presidio Ospedaliero San Paolo and University of Milan, Milan, Italy																														
01/10/18 – 31/09/19																															
04/08/2017	Member of Italian Medical Association Ordine dei Medici e degli Odontoiatri di Catania, n° 15479																														
18/07/17	License to Practice in Medicine and Surgery University of Catania, Catania (Italy)																														
20/10/2011 – 20/03/2017	Medical Doctor, with full marks 110/110 cum laude University of Catania, Catania (Italy) Thesis: Correlation of the germline C8092A polymorphism of the ERCC-1 gene with the response to Nivolumab in patients with metastatic non-small cell lung cancer																														
01/05/2015 – 20/03/2017	Internship in Medical Oncology University of Catania, Catania (Italy)																														
06/03/2017	Basic Life Support-Defibrillation Certificate Italian Resuscitation Council (IRC)																														
2005/2006 – 2009/2010	Secondary School Graduation with full marks 100/100 cum laude Liceo Classico Gulli e Pennisi, Acireale (CT), Italy																														
Scientific affiliations																															
10/09/2022 - Today	Member of FONICAP																														
12/03/2019 - Today	Member of European Society of Medical Oncology (ESMO) ESMO ID 442616																														
15/07/2020 - Today	Member of Italian Association of Medical Oncology (AIOM)																														
2022 - Today	European Organisation for Research and Treatment of Cancer (EORTC)																														
Personal skills																															
Languages	<table><tr><th colspan="2">Understanding</th><th colspan="2">Speaking</th><th>Writing</th></tr><tr><td>Listening</td><td>Reading</td><td>Spoken interaction</td><td>Spoken production</td><td></td></tr><tr><td colspan="5">Italian</td></tr><tr><td colspan="5">Mother tongue</td></tr><tr><td>English</td><td>Excellent</td><td>Excellent</td><td>Very Good</td><td>Excellent</td></tr><tr><td>06/2020</td><td colspan="4">First Certificate in English (FCE)</td></tr></table>	Understanding		Speaking		Writing	Listening	Reading	Spoken interaction	Spoken production		Italian					Mother tongue					English	Excellent	Excellent	Very Good	Excellent	06/2020	First Certificate in English (FCE)			
Understanding		Speaking		Writing																											
Listening	Reading	Spoken interaction	Spoken production																												
Italian																															
Mother tongue																															
English	Excellent	Excellent	Very Good	Excellent																											
06/2020	First Certificate in English (FCE)																														

French	Basic	Basic	Basic	Basic	Basic
	(*) Common European Framework of Reference for Languages				
Social / organisational skills and competences	Good aptitude for teamwork and collaboration. Good organizational skills				
Digital competences	Microsoft Office, MAC OSX and android operating systems (very good knowledge) Internet network use (very good knowledge) Medline database use, e.g. Pubmed (good knowledge) R Studio (basic knowledge)				

Publications

1. Zattarin E, **Beninato T**, Di Liberti G, Lorenzini D, Vingiani A, Leporati R, Occhipinti M, Brambilla M. Breast cancer and large-cell neuroendocrine carcinoma harboring the same PIK3CA mutation: A case report. *Tumori*. 2025 Jul 15;3008916251353357. doi: 10.1177/03008916251353357. Epub ahead of print. PMID: 40665666.
2. Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzone F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Grava L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorria T, Servetto A, **Beninato T**, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 $\geq$ 50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. *J Immunother Cancer*. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674. PMID: 39904562; PMCID: PMC11795382.
3. Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M, Zollo F, Alvisi MF, Perrino M, Cordua N, Borea F, de Vincenzo F, Chella A, Cappelli S, Pardini E, Ballatore Z, Lucarelli A, Ambrosini E, Giuliano M, Pietroluongo E, Mulargiu C, Fabbri A, Prelaj A, Occhipinti M, Brambilla M, Mazzeo L, **Beninato T**, Vigorito R, Ruggirello M, Greco FG, Calareso G, Miliziano D, Rulli E, De Simone I, Torri V, de Braud FGM, Pasello G, De Placido P, Berardi R, Petrini I, Zucali P, Garassino MC, Lo Russo G. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial (NCT03921671). *Ann Oncol*. 2024 Sep;35(9):817-826. doi: 10.1016/j.annonc.2024.06.002. Epub 2024 Jun 8. PMID: 38857846.
4. Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, **Beninato T**, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. *Lung Cancer*. 2025 Jan;199:108051. doi: 10.1016/j.lungcan.2024.108051. Epub 2024 Dec 9. PMID: 39740426.
5. Ambrosini P, Miliziano D, Liberti GD, Lorenzini D, Marchesi S, Bassetti A, Tamborini E, Leporati R, **Beninato T**, Mazzeo L, Brambilla M, Ganzinelli M, Prelaj A, Proto C, Braud FG, Russo GL, Occhipinti M. Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases. *Clin Lung Cancer*. 2025 Jan;26(1):e11-e17. doi: 10.1016/j.clc.2024.11.012. Epub 2024 Nov 25. PMID: 39665942.
6. Provenzano L, Favali M, Mazzeo L, Spagnoletti A, Calareso G, Ruggirello M, Greco G, Vigorito R, Lello A, Zec A, Ferrarin A, Giani C, Silvestri C, Occhipinti M, Brambilla M, Leporati R, Manglaviti S, Cavalli C, Mazzoli G, Miliziano D, Di Liberti G, Moreno MB, Frasca Sarah, Di Mauro R, Abate A, Dumitrascu AD, Serra Cassano T, **Beninato T**, Proto C, Ganzinelli C, Vingiani A, Lorenzini D, Sangaletti S, Restelli M, Trovò F, Marchianò A, Garassino MC, de Braud F, Pedrocchi ALG, Lo Russo G, Miskovic V, Prelaj A. (2024). Integrating radiomics and real-world data to predict immune-checkpoint inhibitors efficacy in advanced Non-Small Cell Lung Cancer. 10.21203/rs.3.rs-4763917/v1.
7. Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, Contedua V, Rebuzzi SE, **Beninato T**, Venturi G, Doni L, Verzoni E, Puglisi S, Landriscina M, Porta C, Manfredi F, Caffo O, De Giorgi U, Fogli S, Danesi R. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer. *Clin Genitourin Cancer*. 2024 Oct;22(5):102147. doi: 10.1016/j.clgc.2024.102147. Epub 2024 Jun 27. PMID: 39030142.

8. Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, **Beninato T**, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Unleashing precision: A review of targeted approaches in pleural mesothelioma. *Crit Rev Oncol Hematol*. 2024 Nov;203:104481. doi: 10.1016/j.critrevonc.2024.104481. Epub 2024 Aug 17. Erratum in: *Crit Rev Oncol Hematol*. 2024 Sep 23:104521. doi: 10.1016/j.critrevonc.2024.104521. PMID: 39159705.
9. **Beninato T**, Lo Russo G, Leporati R, Roz L, Bertolini G. (2024). Circulating tumor cells in lung cancer: Integrating stemness and heterogeneity to improve clinical utility. *International Review of Cell and Molecular Biology*, Academic Press, 2024, ISSN 1937-6448, <https://doi.org/10.1016/bs.ircmb.2024.03.001>.
10. Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, **Beninato T**, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study. *Acta Oncol*. 2024 Apr 21;63:213-219. doi: 10.2340/1651-226X.2024.24179. PMID: 38647024.
11. Leporati R, Miliziano D, **Beninato T**, Mazzeo L, Manglaviti S, Brambilla M, Occhipinti M, Prelaj A, Proto C, Lo Russo G. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs. *Tumori*. 2024 Apr 16:3008916241246659. doi: 10.1177/03008916241246659. Epub ahead of print. PMID: 38623748.
12. Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, Galli G, Agustoni F, Corte CMD, Spagnoletti A, Giani C, Ferrara R, Proto C, Brambilla M, Dumitrascu AD, Inno A, Signorelli D, Pizzutillo EG, Brighenti M, Biello F, Bennati C, Toschi L, Russano M, Cortellini A, Catania C, Bertolini F, Berardi R, Cantini L, Pecci F, Macerelli M, Emili R, Bareggi C, Verderame F, Lugini A, Pisconti S, Buzzacchino F, Aieta M, Tartarone A, Spinelli G, Vita E, Grisanti S, Trovò F, Auletta P, Lorenzini D, Agnelli L, Sangaletti S, Mazzoni F, Calareso G, Ruggirello M, Greco GF, Vigorito R, Occhipinti M, Manglaviti S, **Beninato T**, Leporati R, Ambrosini P, Serino R, Silvestri C, Zito E, Pedrocchi ACL, Miskovic V, de Braud F, Pruneri G, Lo Russo G, Genova C, Vingiani A. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. *Clin Lung Cancer*. 2024 Mar;25(2):190-195. doi: 10.1016/j.clcc.2023.12.012. Epub 2023 Dec 22. PMID: 38262770.
13. Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, **Beninato T**, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. *Lung Cancer*. 2023 Oct 29;186:107417. doi: 10.1016/j.lungcan.2023.107417. Epub ahead of print. PMID: 37918061.
14. Brambilla M, **Beninato T***(corresponding), Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, Lo Russo G, Pizzutillo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. *Clin Lung Cancer*. 2023 Aug 23:S1525-7304(23)00149-3. doi: 10.1016/j.clcc.2023.08.004. Epub ahead of print. PMID: 37775370.
15. Lo Russo G, Prelaj A, Dolezal J, **Beninato T**, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovò F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. *J Immunother Cancer*. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. PMID: 37286305; PMCID: PMC10254948.
16. Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M,

De Toma A, Mazzeo L, **Beninato T**, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. *J Thorac Oncol*. 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009. Epub 2023 Apr 23. PMID: 37094664.

17. Prelaj A, Galli E, Miskovic V, Pesenti M, Viscardi G, Pedica B, Mazzeo L, Bottiglieri A, Provenzano L, Spagnoletti A, Marinacci R, De Toma A, Proto C, Ferrara R, Brambilla M, Occhipinti M, Manglaviti S, Galli G, Signorelli D, Giani C, **Beninato T**, Pircher CC, Rametta A, Kosta S, Zanitti M, Di Mauro MR, Rinaldi A, Di Gregorio S, Martinetti A, Garassino MC, de Braud FGM, Restelli M, Lo Russo G, Ganzinelli M, Trovò F, Pedrocchi A. (2023). Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. *Frontiers in Oncology*. 12. 1078822. 10.3389/fonc.2022.1078822.
18. Zattarin E, Manglaviti S, Apollonio G, **Beninato T**, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSiLoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. *Future Oncol*. 2022 Jul;18(23):2593-2604. doi: 10.2217/fon-2021-1454. Epub 2022 Jun 20. PMID: 35722877.
19. Prinzi N, Corti F, Torchio M, Niger M, Antista M, Pagani F, **Beninato T**, Pulice I, Rossi RE, Coppa J, Cascella T, Giacomelli L, Di Bartolomeo M, Milione M, de Braud F, Pusceddu S. Metastatic pheochromocytomas and paragangliomas: where are we? *Tumori*. 2022 May 20:3008916221078621. doi: 10.1177/03008916221078621. Epub ahead of print. PMID: 35593402.
20. Prelaj A, Boeri M, Robuschi A, Ferrara R, Proto C, Lo Russo G, Galli G, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, **Beninato T**, Bottiglieri A, Massa G, Zattarin E, Gallucci R, Galli EG, Ganzinelli M, Sozzi G, de Braud FGM, Garassino MC, Restelli M, Pedrocchi ALG, Trovò F. Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. *Cancers (Basel)*. 2022 Jan 16;14(2):435. doi: 10.3390/cancers14020435. PMID: 35053597; PMCID: PMC8773718.
21. Ottini A, Sepe P, **Beninato T**, Claps M, Guadalupi V, Verzoni E, Giannatempo P, Baciarello G, de Braud F, Procopio G. Biomarker-driven immunotherapy for precision medicine in prostate cancer. *Per Med*. 2022 Jan;19(1):51-66. doi: 10.2217/pme-2021-0079. Epub 2021 Dec 7. PMID: 34873959.
22. Guarneri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andretta C, Ferro A, Zambelli A, Gori S, Garrone O, Dieci MV, Orlando L, Pastina I, **Beninato T**, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINTenance Afinitor) trial. *Eur J Cancer*. 2021 Sep;154:21-29. doi: 10.1016/j.ejca.2021.05.008. Epub 2021 Jul 2. PMID: 34225066.
23. Fucà G, **Beninato T**, Bini M, Mazzeo L, Di Guardo L, Cimminiello C, Randon G, Apollonio G, Bisogno I, Del Vecchio M, Lauria Pantano C, Di Nicola M, de Braud F, Del Vecchio M. The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy. *Target Oncol*. 2021 Jul;16(4):529-536. doi: 10.1007/s11523-021-00819-0. Epub 2021 Jun 2. PMID: 34076798.
24. Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, **Beninato T**, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung

Cancer With Uncommon Histology. Clin Lung Cancer. 2021 Jul 5:S1525-7304(21)00180-7. doi: 10.1016/j.clcc.2021.06.013. Epub ahead of print. PMID: 34334296.

25. Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, Proto C, **Beninato T**, Zattarin E, Lo Russo G, Gelibter AJ, Simmaco M, Preissner R, Garassino MC, De Braud F, Marchetti P. Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. J Pers Med. 2021 May 18;11(5):424. doi: 10.3390/jpm11050424. PMID: 34069851; PMCID: PMC8157378.
26. **Beninato T**, Fucà G, Di Guardo L, Vetrano I, Valeri B, Nesa F, Del Vecchio M, Cimminiello C. Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors. Melanoma Res. 2021 Apr 1;31(2):178-180. doi: 10.1097/CMR.0000000000000715. PMID: 33492050.
27. Cavalieri S, Orlandi E, Ivaldi E, Bergamini C, Alfieri S, Iacovelli NA, Ingargiola R, Resteghini C, Platini F, Apollonio G, **Beninato T**, Incandela F, Fontanella W, Bresciani L, Giannini L, Piazza C, Licitra L, Locati LD. Management of loco-regionally advanced squamous laryngeal cancer in elderly patients. Eur Arch Otorhinolaryngol. 2021 Mar;278(3):771-779. doi: 10.1007/s00405-020-06179-1. Epub 2020 Jul 12. PMID: 32656672.
28. Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, **Beninato T**, Mazzeo L, Rea CG, Mariani G, de Braud F, Bianchi GV, Vernieri C, Capri G. Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. Ther Adv Med Oncol. 2020 Dec 7;12:1758835920970081. doi: 10.1177/1758835920970081. PMID: 33335565; PMCID: PMC7724266.
29. Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M, Cascella T, Spreafico C, **Beninato T**, Coppa J, Lo Russo G, Di Bartolomeo M, de Braud F, Pusceddu S. Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clin Lung Cancer. 2020 Dec 17:S1525-7304(20)30347-8. doi: 10.1016/j.clcc.2020.12.004. Epub ahead of print. PMID: 33618994.
30. **Beninato T**, Lo Russo G, Garassino MC, De Braud F, Platania M. Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report. Tumori. 2020 Dec;106(6):NP41-NP45. doi: 10.1177/0300891620905665. Epub 2020 Feb 17. PMID: 32066344.
31. Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, **Beninato T**, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med. 2020 Aug 1;9(8):2468. doi: 10.3390/jcm9082468. PMID: 32752158; PMCID: PMC7464810.
32. Ferrara R, Lo Russo G, Ciniselli C, Piva A, Bassani B, Jachetti E, Calareso G, Duroni V, Gregorio S, Proto C, Prelaj A, De Toma A, Occhipinti M, Brambilla M, Manglaviti S, Mazzeo L, Rinaldi A, **Beninato T**, Ganzinelli M, Sangaletti S. (2023). Abstract 5506: Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations. Cancer Research. 83. 5506-5506. 10.1158/1538-7445.AM2023-5506.
33. Miceli R, Eriksson H, Eustace A, Lo Russo G, Alfieri S, Bjaanæs M, Pietrantonio F, Cecco L, Prelaj A, Proto C, Franzen J, McDonnell D, Berenguer-Pina J, **Beninato T**, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å. (2023). Sex differences in burden of adverse events in patients receiving immunotherapy. Journal of Clinical Oncology. 41. 2646-2646. 10.1200/JCO.2023.41.16_SUPPL.2646.

34. Mazzeo L, **Beninato T**, Pircher C, Brambilla M, Manglaviti S, De Toma A, Galli G, Prelaj A, Ferrara R, Proto C, Lo Russo G, Ganzinelli M, Garassino M, Marchetti P, De braud F, Occhipinti M. (2022). Immunotherapy and chemo-immunotherapy for non-small cell lung cancer with novel actionable oncogenic driver alterations. *Journal of Clinical Oncology*. 40. 9057-9057. 10.1200/JCO.2022.40.16_suppl.9057.
35. Occhipinti M, Brambilla M, Galli G, Manglaviti S, Prelaj A, Ferrara R, De Toma A, **Beninato T**, Zattarin E, Proto C, Lo Russo G, Gelibter A, Simmaco M, Garassino M.C., Marchetti P. (2021). 133P Drug-drug interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment. *Journal of Thoracic Oncology*. 16. S769-S770. 10.1016/S1556-0864(21)01975-4.
36. Manglaviti S, Galli G, Bini M, Labianca A, Zecca E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, **Beninato T**, Zattarin E, Ganzinelli M, Braud F.G.M., Garassino M.C., Lo Russo G, Ferrara R. (2021). 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs). *Journal of Thoracic Oncology*. 16. S797. 10.1016/S1556-0864(21)02026-8.
37. Vernieri C, Nichetti F, Ligorio F, Zattarin E, **Beninato T**, Lobefaro R, Bianchi G, Capri G, Garassino M, Lo Russo G, Del Vecchio M, Corsetto P, Rivoltini L, Castelli C, de Braud F. (2020). Abstract CT198: Efficacy of metformin in Preventing glucocorticoid-induced diabetes in Melanoma, breast or Lung Cancer patients with brain metastases: The phase II OPTIMAL study. CT198-CT198. 10.1158/1538-7445.AM2020-CT198.
38. Torchio M, Corti F, Manca P, Prinzi N, Platania M, Maurichi A, Mattavelli I, Patuzzo R, Bedini N, Milione M, Cattaneo L, **Beninato T**, Prisciandaro M, Raimondi A, Pagani F, Colombo E, Coppa J, Di Bartolomeo M, Braud F.G., Pusceddu S. (2020). 1182P Baseline neutrophil-lymphocyte ratio and its variations after adjuvant radiotherapy predict clinical survival outcomes in locally advanced Merkel cell carcinoma (MCC). *Annals of Oncology*. 31. S781. 10.1016/j.annonc.2020.08.1395.
39. Blasi M, Marra A, Violati M, **Beninato T**, Bordin V, Broggio F, Carla C, Luciani A, Barabino M, Giovenzana M, Santambrogio R, Ferrari D. (2018). B27 Clinical Outcomes After Curative Resection of Colorectal Cancer Liver Metastases: A Single Institution Experience. *Tumori*. 104. 10.1177/0300891618796945.
40. Prelaj A, Boeri M, Robuschi A, Proto C, Lo Russo G, Ferrara R, Galli G, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Labianca A, **Beninato T**, Bini T, Mensah M, Ganzinelli M, Zilembo N, de Braud F, Sozzi G, Restelli M, Pedrocchi A, Garassino MC and Trovo F. PO-065: Artificial intelligence to improve selection for NSCLC patients treated with immunotherapy. *Clin Cancer Res* March 1 2021 (27) (5 Supplement). 10.1158/1557-3265.ADI21-PO-065
41. Ferrara R, Jachetti E, Calareso G, Brambilla M, Lo Russo G, Proto C, Prelaj A, Signorelli D, Galli G, De Toma A, Occhipinti M, Manglaviti S, Labianca A, Ganzinelli M, Spanò SM, Molino G, Martinetti A, Greco FG, Bini M, **Beninato T**, de Braud F, Colombo MP, Garassino MC and Sangaletti S. Abstract 1669: Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts). *Cancer Res* July 1 2021 (81) (13 Supplement) 1669; DOI: 10.1158/1538-7445.AM2021-1669
42. Corti F, Amoroso V, Campana D, Brizzi MP, Panzuto F, Puliafito I, Prinzi I, Milione M, Nigro M, Antista M, Raimondi A, Morano F, Prisciandaro M, **Beninato T**, Pagani F, Randon G, Pulice I, Di Bartolomeo M, G. De Braud F, and Pusceddu S. Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial. *Journal of Clinical Oncology* 2021 39:15_suppl, TPS4167-TPS4167

43. Ferrara R, Lo Russo G, Ciniselli CM, Di Gregorio S, Calareso G, Bassani B, Proto C, Prelaj A, De Toma A, Occhipinti M, Brambilla M, Manglaviti S, Mazzeo L, **Beninato T**, Ganzinelli M, De Braud FGM, Garassino MC, Colombo MP, Verderio P, Sangaletti S. 1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations. Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064
44. **Beninato T**, Brambilla M, Pircher CC, Mazzeo L, Rametta A, Manglaviti S, De Toma A, Galli G, Prelaj A, Ferrara R, Proto C, Lo Russo G, Ganzinelli M, Di Mauro R, Di Nucci A, Garassino MC, Marchetti P, De Braud FGM, Occhipinti M. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064
45. Prelaj A, Bottiglieri A, Provenzano L, Spagnoletti A, Mazzeo L, Miskovic V, Ganzinelli M, Lo Russo G, Ferrara R, Proto C, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, **Beninato T**, Rametta A, Garassino MC, De Braud FGM, Trovò F, Pedrocchi A. 1071P - Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients. Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064
46. Bottiglieri A, Provenzano L, Spagnoletti A, Mazzeo L, Ganzinelli M, Lo Russo G, Ferrara R, Proto C, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, **Beninato T**, Garassino MC, Filosa J, Di Guida G, De Braud FGM, Viscardi G, Della Corte GM, Prelaj A. 1056P - KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC. Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064.
47. Leporati R, **Beninato T**, Iadecola S, Andreon C, Murianni F, Balsamo M, Martinetti A, Lombardi Stocchetti B, Mazzeo L, Manglaviti S, Occhipinti M, Brambilla M, Prelaj A, Proto C, Miceli R, Roz L, Sozzi G, De Braud F, Lo Russo G, Bertolini G. Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3702.

Il sottoscritto TERESA BENINATO, ai sensi di quanto previsto dagli artt. 19, 46 e 47 del D.P.R. 445/2000, consapevole delle conseguenze derivanti in caso di rilascio di dichiarazioni false, dichiara sotto la propria responsabilità che tutte le eventuali fotocopie allegate alla domanda di partecipazione al pubblico concorso, sono conformi all'originale in suo possesso e che ogni dichiarazione resa risponde a verità.

In compliance with the GDPR and Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned Decree.

Milano, 22 Luglio 2025

